XIAP Polyclonal Antibody

disease:Defects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.,domain:The first BIR domain is involved in interaction with MAP3K7IP1 and is important for dimerization. The second BIR domain is sufficient to inhibit caspase-3 and caspase-7, while the third BIR is involved in caspase-9 inhibition. The interactions with SMAC and PRSS25 are mediated by the second and third BIR domains.,function:Apoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.,online information:XIAP mutation db,PTM:Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.,PTM:Ubiquitinated and degraded by the proteasome in apoptotic cells.,similarity:Belongs to the IAP family.,similarity:Contains 1 RING-type zinc finger.,similarity:Contains 3 BIR repeats.,subunit:Monomer, and homodimer. Interacts with SMAC and with PRSS25; these interactions inhibit apoptotic suppressor activity. Interacts with MAP3K7IP1 and AIFM1. Interaction with SMAC hinders binding of MAP3K7IP1 and AIFM1. Interacts with TCF25.,tissue specificity:Ubiquitous, except peripheral blood leukocytes.,